Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• the present application relates to compositions and methods for the treatment of respiratory diseases. It also relates to compositions and methods for regulating the paracellular permeability of pulmonary epithelium.
• the compositions and methods of the invention are based in particular on the use of agents or conditions modulating the cytoskeletal tension of pulmonary epithelial cells.
• the invention is useful for the preventive or curative treatment of various pathologies, such as asthma, allergies, obstructive diseases, etc., in mammals, especially humans.
• the pulmonary epithelium is the center of very important exchanges between the external environment and the organism. These exchanges can take place either through the cells of the epithelium or through parallel networks.
• the transport of water or electrolytes, or the absorption of small molecules (molecular weight generally less than about 1000 Da) in the gastric mucosa, intestinal or colonic is carried out transcellularly, through epithelial cells or enterocytes.
• the absorption of large molecules and the passage of toxins or immune cells is mainly paracellular, at the level of "tight junctions", which are arranged between the epithelial cells.
• TJ tight junctions epithelial
• the tight junctions epithelial are structures of connection between the cells bordering the mucous epithelia (digestive tract, lungs). These structures provide and control the transepithelial paracellular transport, from the outside to the submucosa, of various macromolecules (irritants, microorganisms). These structures also allow the migration of immune cells (eg, immunocytes) to the outside.
• Tight junctions are flexible structures consisting of a complex assembly of transmembrane proteins (occludins, claudines) and cytoplasmic proteins (zona ocludens ZO-1, ZO-2, ZO-3 proteins, AF7 proteins, cingulin or 7H6, etc.), variable according to the epithelia considered, which are associated to elements of the cytoskeleton (filaments of myosin, actin, etc.).
• agents disrupting the actin cytoskeleton have been shown to increase the activity of NO synthase in endothelial cells (WO00 / 03746).
• the allergen sensitization process is a very important risk factor in the development of allergies and asthma.
• the mechanisms by which allergens are able to initiate the sensitization phenomenon are not clearly documented in vivo.
• allergens When allergens are inhaled, they come into contact with the pulmonary epithelial wall which prevents their introduction into the body and their contact with the cells of immunity.
• the conditions under which this transfer is possible remain poorly documented in vivo.
• some reports suggest, on in vitro cell cultures, a role of tight junctions in this process, no demonstration has been made of the involvement of these junctions in vivo in the development of sensitization.
• the present application results from the demonstration of an in vivo role of the tight junctions of the pulmonary epithelium in the allergen sensitization process.
• the present application also results from the development of new therapeutic strategies for the treatment of respiratory pathologies, based on a modulation of the para-cellular permeability of the pulmonary epithelium.
• the present application proposes, for the first time, a therapeutic approach to respiratory pathologies based on the use of compounds or conditions for modulating the cytoskeletal tension of pulmonary epithelial cells. This approach makes it possible in particular to control the opening and closing of the tight junctions of the pulmonary epithelium, without necessarily resorting to de novo protein synthesis and / or to significant protein and / or structural degradations at the level of the epithelium.
• This strategy makes it possible to regulate the permeability of the pulmonary epithelium in a specific, fine and reactive manner, and thus to act on the transfer of allergens to the cells of the immunity.
• This strategy is particularly adapted to obtaining a rapid and controllable biological effect over time (reversible).
• the results presented in the application show that substances capable of relaxing the tight epithelial junctions (PAR-2 receptor activating peptide, LPS) promote the alveolar accumulation of neutrophils and eosinophils, as is observed in bronchial diseases. -sulmonary such as asthma.
• results show that a chemical capable of reducing the permeability of the tight junctions of the pulmonary epithelium prevents the accumulation of neutrophils and eosinophils.
• results provide evidence that molecules, agents, conditions or processes that can reduce or suppress the opening of the tight junctions of the pulmonary alveolar or bronchial epithelium are of interest in the treatment of pulmonary diseases, particularly those characterized by intrabronchial and alveolar neutrophils or eosinophils, especially asthma.
• a first object of the invention therefore lies more particularly in the use of a compound modulating the cytoskeletal tension of pulmonary epithelial cells, for the preparation of a medicament intended for the preventive or curative treatment of respiratory pathologies, preferably at least one patient.
• exclusion of hypoxia caused by these conditions in particular excluding hypoxia caused by pulmonary dysfunction.
• pulmonary dysfunction may be caused by emphysema, cigarette smoke, chronic bronchitis, asthma, infectious agents, pneumonitis (infectious or chemical), lupus, rheumatoid arthritis, congenital disorders such as cystic fibrosis, obesity and hereditary deficiency in antitrypsin.
• Hypoxia is defined herein as the decrease below the normal level of oxygen in a tissue.
• Another subject of the invention resides in a method of preventive or curative treatment of respiratory pathologies, comprising the administration to a subject of a effective amount of a compound modulating the cytoskeletal tension of pulmonary epithelial cells.
• the invention thus relies on the use of compounds modulating the tension and the state of contraction of the cytoskeleton of the cells of the pulmonary epithelium.
• this approach makes it possible to control the opening and closing of the tight junctions of the pulmonary epithelium, without necessarily resorting to de novo protein synthesis and / or to significant protein and / or structural degradations at the level of the lung. 'epithelium.
• the proteins composing the tight junctions are associated with the cytoskeleton of the cells they connect. It is proposed in the context of the invention that the cytoskeletal tension can be modulated in subjects with respiratory diseases or disorders to act in a non-destructive and transient manner on the permeability of their pulmonary epithelium. Thus, the contraction of the cytoskeleton should favor the opening of the tight junctions, while a relaxation of the cytoskeleton (or an inhibition of the contraction) should favor the closing of the junctions.
• Compounds (or conditions) that modulate the contraction of the cytoskeleton of pulmonary epithelial cells are preferably used in the context of the invention, preferably without substantially (substantially) modulating the permeability of the vascular endothelium and / or pulmonary circulatory hemodynamics.
• compounds that inhibit or stimulate or promote the contraction of the cytoskeleton of pulmonary epithelial cells are used.
• the activity of the compound on the cytoskeletal tension may be direct or indirect, that is, directed to the very constituents of the cytoskeleton or regulators of its voltage.
• the compounds are preferred acting directly on the cytoskeletal tension.
• compounds with selective cytoskeletal voltage-selective activity are also preferred, that is, typically compounds that do not directly affect the structure of the tight junction proteins.
• a compound is considered to modulate the cytoskeletal tension as it modulates the opening of tight junctions.
• An inhibitory effect of the contraction does not have to be complete or complete, but it suffices that it diminishes the contraction sufficiently to reduce the opening of the tight junctions corresponding to a minimum decrease of about 30% of the paracellular permeability of the pulmonary epithelium, preferably about 40%, more preferably about 50%.
• the term "compound” must be taken in a broad sense, that is to say as designating any agent, substance, composition, condition, treatment or process that modulates the cytoskeleton tension. . It is advantageously an agent (e.g., a molecule) or a combination or combination of molecules.
• inhibiting compounds (or modulators) of the contraction of the myosin light chain, or inhibitory (or modulating) compounds of the degradation of actin are used.
• a particularly preferred mode of implementation of the invention lies in the use of compounds which inhibit the contraction of the myosin light chain or the degradation of actin, preferentially compounds which inhibit the phosphorylation of the light chain.
• myosin Such compounds that inhibit myosin light chain phosphorylation may be inhibitors of myosin light chain kinase (MLCK).
• a particular example of a selective MLCK inhibitor is ML-7 ⁇ 1- (5-iodonaphthalene-1-sulfonyl) -1H-hexahydro-1,4-diazepine ⁇ (Makishima M. et al., FEBS Lett 1991; 287: 175).
• Other examples of such inhibitors include ML-9 (Wilson DP et al., J Biol Chem 2001; 13: 165) or other non-selective ones: Wortmannin (Warashina A. Life Sci 2000; 13: 2587). -93), H-7 (Piao Zf et al Mol Cell Biol Res Commun 2001; 4: 307-12) and KT 7692 (Warashina A.
• a preferred object of the invention is the use of MLCK inhibiting compounds selected from ML-7, ML-9, Wortmannin, H-7 and KT 7692, alone or in combination.
• Preferred compounds of the invention are compounds having no significant or substantial effect on vascular permeability and / or pulmonary circulatory hemodynamics.
• MLCK inhibiting compounds are used with the exception of BDM [2,3-butanedione 2-monoxime], ML-7, ML-9 [1- (5-chloronaphthalene) 1-sulfonyl) -1H-hexahydro-1,4-diazepine hydrochloride], wortmannin, H-7 [1- (5-isoquinoline sulphonyl) -2-methylpiperazine dihydro-chloride], Fasudil (HA ⁇ 077) [Hexahydro 1- ( 5-isoquinolinesulphonyl) -1H-1,4-diazepine], W-7 [N- (6-aminohexyl) -5-chloro-1-naphthalenesulfonamide] and A-3 [N- (6-Aminoethyl) -5- chloro-1-naphthalenesulfonamide].
• Other compounds that inhibit the phosphorylation of the myosin light chain may be used with the exception of
• myosin binding proteins such as, for example, cingulin, or the junction molecules, such as E-cadherin, ⁇ -catenin or desmosomes. Modulation of the activity or expression of these proteins allows regulating the cytoskeletal tension in the context of the present invention.
• a particular object of the invention therefore lies in the use of a modulator (especially an inhibitor) of the activity or the structure or expression of cytoskeletal molecules.
• the compound may be for example an antisense nucleic acid, a synthetic molecule, an antibody fragment, etc.
• inhibiting compounds of protein synthesis or other molecules that bind cytoskeletal proteins to tight junction proteins may be used.
• proteins of the tight junctions mention may be made in particular of the occludin, claudin, ZO-1, ZO-2, ZO-3, AF7 and 7H6 proteins.
• One means according to the invention of modulating the opening or the closing of the tight junctions resides in the regulation of the synthesis of the binding proteins between the cytoskeleton and the proteins of the tight junctions. By stimulating this synthesis, it is expected a strengthening of the bonds between the tight junctions and the cytoskeleton, leading to a lower permeability of the epithelium.
• MAPKK mitogen-activated kinase inhibitors
• MEK1 kinase or PI3 kinase such as PD098,059 ⁇ 2- ( Amino-3-methoxyphenyl) -4H-1-benzopyran-4-one (Alessi et al., J.Biol.Chem.1995; 270, 27589) or LY294002 ⁇ 2- (4-Morpholinyl) -8phenyl-1 (4H); ) -benzopyran-4-one ⁇ (Vlahos et alJ.Biol.Chem 1994; 269: 5241).
• MAPKK mitogen-activated kinase inhibitors
• HGF hepatic growth factor
• EGF endothelial growth factor
• cytokines capable of being released by immunocytes, such as interleukins-1, -4, -13, or factors such as IGF-1 or interferon gamma.
• Another approach for indirectly regulating the cytoskeletal tension is based on the use of taurine or GLP2 peptide ("glucagon-like peptide 2") or derivatives thereof, which can make it possible to alter the permeability of the pulmonary epithelium by an indirect effect on the contraction of the cytoskeleton.
• certain molecules acting on receptors located at the apical pole of epithelial cells eg: proteinase receptors, PAR-2
• a preferred embodiment of the invention comprises the use of agents acting directly on the cytoskeletal tension, in particular molecules that inhibit the contraction of the cytoskeleton, in particular molecules that inhibit the contraction of the light chain.
• myosin, or inhibitors of the degradation of actin preferentially compounds which inhibit the phosphorylation of the myosin light chain.
• the compounds used are advantageously molecules, which may be in isolated form or in combination form, biological extracts, etc. These molecules can be synthetic, semi-synthetic or biological, in particular of animal, viral, plant or bacterial origin.
• the present invention may be used for the treatment or the management of pathologies or disorders of the respiratory system, in particular asthma, allergies, obstructive pathologies (bronchitis, bronchiolitis, emphysema, etc.), especially when these pathologies have a particular problem. chronic or severe character. It is particularly adapted to the preventive or curative treatment of asthma or various allergies (dust, pollen, pollution, etc.) as well as local treatment of pulmonary inflammation. It can be used preventively in subjects with predispositions or sensitivity to this type of disorder, or in a curative manner, for example during seizures or over longer periods.
• the compositions and methods of the invention make it possible to reduce the suffering or the respiratory difficulties of the subjects, to reduce the symptoms or the cause of these disorders.
• a particular object of the invention lies in the use of a compound as defined above for the preparation of a medicament intended to control, in particular to reduce the paracellular permeability of the pulmonary epithelium in subjects suffering from diseases respiratory, including pulmonary diseases characterized by intrabronchial and alveolar accumulation of neutrophils or eosinophils, for example asthma or allergy.
• Another particular object of the invention resides in the use of a compound as defined above for the preparation of a medicinal product intended to reduce allergen sensitization in subjects suffering from or sensitive to respiratory diseases, particularly diseases.
• pulmonary systems characterized by intrabronchial and alveolar accumulation of neutrophils or eosinophils, eg asthma or allergy.
• Another particular object of the invention resides in the use of a compound as defined above for the preparation of a medicament for reducing the transepithelial migration of immunocytes and the accumulation of immunocytes in the lung of subjects with a respiratory condition, including a lung condition characterized by intrabronchial and alveolar accumulation of neutrophils or eosinophils, eg asthma or allergy.
• the invention also relates to methods of treatment of the conditions indicated above, comprising the administration to a subject suffering from a respiratory pathology or sensitive to respiratory diseases, a compound or treatment as defined above.
• the compound or treatment is administered in a dose effective to reduce paracellular permeability of the pulmonary epithelium and / or to reduce allergen sensitization and / or to reduce transepithelial migration of immunocytes and accumulation of immunocytes. in the lung.
• the compound can be administered by different routes and in different forms.
• the compound may be in liquid, solid or aerosol form, typically in the form of a tablet, capsule, aerosol, ampoule or oral solution, injectable solution, etc.
• Compounds formulated in adminiscable form are preferred locally (e.g., in the airways (e.g., respiratory)) or orally (oral solutes, tablets, ampoules, syrups, sprays, etc.). Aerosol packaging is particularly preferred where possible.
• other forms of administration are possible, such as injections (intradermal, subcutaneous, intramuscular, intravenous, intraarterial, intraperitoneal, etc.), pastes, gels, suppositories, etc.
• the compounds can be used alone or in combination and / or in combination with other active agents, for example other active substances used in the treatment of respiratory diseases.
• active agents for example other active substances used in the treatment of respiratory diseases. Examples which may be mentioned include ⁇ 2-agonists and anti-cholinergic compounds, corticosteroids, anti-leukotrienes, etc. These different agents can be used in therapeutic combination, and administered in separate, combined, time-spread or concomitant form.
• Another subject of the invention is a product or a pharmaceutical combination comprising at least one modulating compound of the blood pressure.
• compositions comprising at least one pulmonary epithelial cell cytoskeleton tension-modulating compound according to the invention, preferably a compound inhibiting the contraction of the myosin light chain, more particularly a compound inhibiting the phosphorylation of the myosin light chain, more particularly an MLCK inhibitor or a myosin phosphatase activator, and a pharmaceutically acceptable carrier, said composition being formulated preferentially for oral or aerial administration.
• the composition is in aerosol form and comprises a carrier gas, or in the form of an oral solution.
• the pulmonary epithelial cell cytoskeleton modulator compound used as a pharmaceutical active agent is used in therapeutically effective amounts. It is understood that the dose administered may be adapted by those skilled in the art depending on the subject (patient) to be treated, the pathology concerned, the mode of administration, etc.
• the amounts or doses of the compounds administered or used in the compositions according to the invention can be determined according to their ability to modulate the cytoskeletal tension of pulmonary epithelial cells. This capacity and therefore the evaluation of the dose to be administered can in particular be determined by the experimental protocol described in Example 7.
• FIG. 1 Influence of ML-7 on the increase in paracellular pulmonary permeability of T-labeled human serum albumin induced by intratracheal perfusion of Pseudomonas aeruginosa LPS.
• LPS decreases the levels of radioactivity measured in bronchoalveolar lavage fluids (LBAs) whereas, compared with controls, these levels are significantly higher in the lungs.
• LBAs bronchoalveolar lavage fluids
• This increase in pulmonary permeability is suppressed by pre-treatment of animals with ML7. Indeed, values similar to the control values of radioactivity levels in both LBAs and lungs were measured in these animals.
• FIG. 2 Western blot of phosphorylated forms of the myosin light chain (p-MLC) and the native form (MLC) following the treatment of human bronchial cells NCI-H292 in culture by LPS. Incubation times are indicated on each blot (T corresponding to the control).
• p-MLC myosin light chain
• MLC native form
• the bronchial and alveolar epithelium has epithelial cell binding structures that provide controlled passage of immunocytes through the airways.
• This example shows that certain molecules known for their effect of increasing paracellular permeability at the intestinal level such as SLIGRL promote the intra-alveolar accumulation of immunocytes. (neutrophils, macrophage) and that this effect can be prevented (eg, inhibited, reduced) by oral treatment with taurine.
• ML-7 reduces the intra-alveolar accumulation of immunocytes observed after intratracheal infusion of taurocholate associated with the opening of tight junctions.
• Control sterile water infused 20 min tracheally; 5 mM Taurocholate infused tracheally; ML7 (1 mg / kg / 12 h, 36 h IP) + Taurocholate * p ⁇ 0.001 significantly different from control values
• Control NaCl 0.9% sterile infused 20 min intratracheally; taurocholate 5mM: rat perfused tracheally; PD-98059 (1 mg / kg / 12 h, 36 h) ⁇ taurocholate.
• Example 4 Inhibition by ML7 of the increase in pulmonary permeability induced by Pseudomonas aeruginosa LPS in rats.
• ML7 Myosin Light Chain Kinase Inhibitor, MLCK
• LPS Intrcerebral lipopolysaccharide
• Pulmonary permeability was measured using a tracer, 125 I- labeled human serum albumin, which, after intratracheal infusion, is measured in urine, plasma, lung tissue and bronchoalveolar lavage.
• this example shows that Pseudomonas aeruginosa LPS increases the paracellular permeability at the pulmonary level favoring the accumulation of immunocytes at the pulmonary level and that this effect can be prevented by a treatment involving an MLCK blocker.
• Example 5 ML-7 Reduction of Pseudomonas aeruginosa LPS-induced Bronchial Inflammatory Response in Rats
• This example complements the previous example and illustrates the reduction, by the ML7, of the bronchial inflammatory response induced by Pseudomonas Aeruginosa LPS administered by intra-tracheal perfusion.
• ML-7 thus reduces the intra-alveolar accumulation of immunocytes.
• Control 5% bovine albumin + PBS solution infused 20 min intratracheally; LPS 1 ⁇ g / rat perfused tracheally; ML-7 (3 mg / kg then 1 mg / kg 3 times daily for 48h IP) + LPS * p ⁇ 0.05 significantly different from the control values. # p ⁇ 0.05 significantly different from LPS values.
• Example 6 Stimulation of the phosphorylation of the myosin light chain of human bronchial epithelial cells by LPS.
• the human cell line used NCI-H292 was obtained from the American Type Culture Collection (Manassas, VA).
• the reagents used, RPMI 1640 medium, fetal calf serum and other cell culture reagents were provided by GIBCO, the protease inhibitor cocktail by ROCHE (1697498) and LPS (E.coli S055: B5) and other reagents. by SIGMA.
• NCI-H292 cells were cultured on RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 U / ml penicillin, 100 ⁇ g / ml streptomycin and 10% fetal calf serum.
• the cells were cultured at 37 ° C in humidified air containing 5% C0 2 and subcultured twice a week.
• the cells were disseminated in 6-well plates, each containing 5 ⁇ 10 cells.
• the cells were incubated in RPMI 1640 containing 0.1% Bovine Serum Albumin (BSA) overnight.
• BSA Bovine Serum Albumin
• the cells are then rinsed with RPMI 1640 without BSA and exposed to LPS (2 ⁇ g / ml) or to physiological saline as a control (0.9% NaCl) for periods ranging from 30 minutes to 24 hours.
• Proteins from the NCI-H292 cells exposed to LPS were separated by SDS-PAGE in a 15% polyacrylamide gel and electrophoretically transferred onto nitrocellulose membrane in 25 mM Tris-amino, 192 mM glycine and 20% methanol.
• Immunoprecipitation was performed with a 1/500 diluted human phosphorylated goat anti-myosin antibody (Santa Cruz Biotechnology Inc.) or a human anti-myosin mouse monoclonal antibody (light chains 20K, Sigma-Aldrich, Inc. ) diluted 1/1000, for the detection of p-MLC and MLC-20, respectively.
• Recombinant peroxidase-Protein G was used at 1/1000 dilution as a secondary antibody.
• the immunolabeled bands were revealed by fluorography with ECL reagent (Enhanced Chemiluminescence, Pierce, Perbio Science, Inc.).
• In vitro screening of pharmaceutical formulations can be an effective and cost-effective method for identifying the lead candidate prior to in vivo testing.
• the cells produce tight junctions that inhibit the passage of low molecular weight solution substances and electrical current flow, allowing the use of trans-epithelial resistance (RTE) as a permeability correlate.
• RTE trans-epithelial resistance
• Pseudomonas aeriginosa LPS decreases the electrical resistance in a dose-dependent manner.
• the data obtained corresponding to the maximum dose inducing a response with the maximum decrease of the TEN is considered as the 100% response and is reported for the test compounds.
• Test compounds Using the same protocol with the maximum dose of LPS (100% response), the test compounds are incubated 1 hour earlier at concentrations varying from 10 ⁇ M to 500 ⁇ M.
• the doses of the test compounds selected for future investigations or tests are the concentrations for which there is a 50% reversal of the maximum decrease in LPS-induced TEN.
• This assay can be used to evaluate the 50% inhibitory effect of test compounds on the decrease of TEN following LPS exposure of cellular monolayers from human bronchial epithelial cells (NCI-H292).

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26213306

Family Applications (1)

Country Status (12)

Families Citing this family (8)

Citations (1)

Family Cites Families (10)

• 2002
  • 2002-07-09 FR FR0208606A patent/FR2833840B1/fr not_active Expired - Fee Related
  • 2002-12-18 SV SV2002001439A patent/SV2003001439A/es not_active Application Discontinuation
  • 2002-12-18 UY UY27589A patent/UY27589A1/es not_active Application Discontinuation
  • 2002-12-19 AR ARP020104998A patent/AR038042A1/es not_active Application Discontinuation
  • 2002-12-20 TW TW091136815A patent/TW200305447A/zh unknown
  • 2002-12-20 CA CA002470442A patent/CA2470442A1/fr not_active Abandoned
  • 2002-12-20 PA PA20028562701A patent/PA8562701A1/es unknown
  • 2002-12-20 EP EP02805413A patent/EP1455767A2/fr not_active Withdrawn
  • 2002-12-20 US US10/498,094 patent/US20050019314A1/en not_active Abandoned
  • 2002-12-20 US US10/324,958 patent/US20030125321A1/en not_active Abandoned
  • 2002-12-20 AU AU2002364679A patent/AU2002364679A1/en not_active Abandoned
  • 2002-12-20 WO PCT/FR2002/004506 patent/WO2003053422A2/fr not_active Application Discontinuation
• 2003
  • 2003-01-06 PE PE2003000015A patent/PE20030853A1/es not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events